GlaxoSmithKline Pharmaceuticals Share: Motilal Oswal Financial Services neutral on GlaxoSmithKline Pharmaceuticals; target price: Rs 1300 - The Economic Times
Haleon or GSK – which is the better play?
GSK Needs to Show It's Kicked the Dealmaking Addiction - The Washington Post
GSK lines up Rs 6,400cr open offer - Times of India
GSK falls victim to 'hard to please' pharma market | LSE:GSK, NYSE:GSK
GSK (GSK) Stock Price, News & Info | The Motley Fool
Leading UK pharma & biotech companies by market cap 2023 | Statista
GlaxoSmithKline: Back To The Drawing Board (NYSE:GSK) | Seeking Alpha
Better Buy: GlaxoSmithKline vs. Eli Lilly | The Motley Fool
Investors in GSK (LON:GSK) have unfortunately lost 8.3% over the last three years - Simply Wall St News
Elliott Publishes Letter on GlaxoSmithKline
Glaxo (GSK) to Report Q1 Earnings: What's in the Cards?
4 Reasons Why You Should Add Glaxo (GSK) to Your Portfolio
Why are GlaxoSmithKline (GSK) shares so low? (LON:GSK) - Good Money Guide
Top-10 Biggest UK-based Companies 2023 | Hantec Markets
Glaxo (GSK) to Report Q4 Earnings: What's in the Cards?
Glaxo (GSK) Q4 Earnings Lag Estimates, Shingrix Back on Track
Better Buy: Eli Lilly vs. GlaxoSmithKline | The Motley Fool
Elliott Publishes Letter on GlaxoSmithKline
Glaxo's (GSK) Q1 Earnings Top, Xevudy Adds $1.7B in Sales | Nasdaq
GSK Stock Price and Chart — LSE:GSK — TradingView
Glaxo (GSK) Q4 Earnings Top Estimates, Xevudy Adds $1.1B in Sales | Nasdaq
GSK spinoff starts trading at LSE - what you need to know
Consumer goods arm of GSK hits stock market | This is Money
UK Drugmaker GSK Needs to Show It's Kicked the Dealmaking Addiction - Bloomberg
Unilever Needs $10 Billion Bump to Win Glaxo Unit, Analysts Say - BNN Bloomberg
Drug wars: how AstraZeneca overtook GSK in UK pharma
